- Home
- TNGX vs ATYR Comparison
TNGX vs ATYR Comparison
Compare TNGX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ATYR
- Stock Information
- Founded
- TNGX 2014
- ATYR 2005
- Country
- TNGX United States
- ATYR United States
- Employees
- TNGX N/A
- ATYR N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNGX Health Care
- ATYR Health Care
- Exchange
- TNGX Nasdaq
- ATYR Nasdaq
- Market Cap
- TNGX 351.2M
- ATYR 306.2M
- IPO Year
- TNGX N/A
- ATYR 2015
- Fundamental
- Price
- TNGX $5.63
- ATYR $5.31
- Analyst Decision
- TNGX Strong Buy
- ATYR Strong Buy
- Analyst Count
- TNGX 6
- ATYR 6
- Target Price
- TNGX $12.20
- ATYR $20.20
- AVG Volume (30 Days)
- TNGX 3.4M
- ATYR 3.5M
- Earning Date
- TNGX 08-06-2025
- ATYR 08-12-2025
- Dividend Yield
- TNGX N/A
- ATYR N/A
- EPS Growth
- TNGX N/A
- ATYR N/A
- EPS
- TNGX N/A
- ATYR N/A
- Revenue
- TNGX $40,990,000.00
- ATYR N/A
- Revenue This Year
- TNGX N/A
- ATYR $960.85
- Revenue Next Year
- TNGX N/A
- ATYR $1,283.47
- P/E Ratio
- TNGX N/A
- ATYR N/A
- Revenue Growth
- TNGX 10.09
- ATYR N/A
- 52 Week Low
- TNGX $1.03
- ATYR $1.48
- 52 Week High
- TNGX $12.02
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- TNGX 77.32
- ATYR 57.23
- Support Level
- TNGX $4.80
- ATYR $4.96
- Resistance Level
- TNGX $5.63
- ATYR $5.47
- Average True Range (ATR)
- TNGX 0.52
- ATYR 0.37
- MACD
- TNGX -0.03
- ATYR -0.07
- Stochastic Oscillator
- TNGX 83.33
- ATYR 61.11
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.